Advertisement

U.S. markets open in 1 hour 53 minutes

S&P Futures
4,519.25
+10.75(+0.24%)
Dow Futures
34,197.00
+195.00(+0.57%)
Nasdaq Futures
15,829.00
-40.75(-0.26%)
Russell 2000 Futures
2,161.20
+14.90(+0.69%)
Crude Oil
65.98
+0.41(+0.63%)
Gold
1,779.60
-4.70(-0.26%)

Advertisement

COMING UP

Jobless claims: Economists expect claims to rise after reaching 52-year low last week

Check back at 8:30 a.m. ET for the resutls

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

4.7800

-0.2600

(-5.16%)

At close: 04:00PM EST

4.8000

+0.02

(+0.42%)

Pre-Market:

07:16AM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Long-term KST

View all chart patterns

Performance Outlook

Previous Close	5.0400
Open	5.1500
Bid	0.0000 x 800
Ask	0.0000 x 1100
Day's Range	4.7633 - 5.1500
52 Week Range	4.7630 - 25.9000
Volume	295,750
Avg. Volume	329,443

Market Cap	89.94M
Beta (5Y Monthly)	-0.03
PE Ratio (TTM)	N/A
EPS (TTM)	-1.7620
Earnings Date	Feb 23, 2022 - Feb 28, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	36.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NOVN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Novan, Inc.
EGRX: Lowering target price to $42.00EAGLE PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $42.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
7 months agoArgus Research

All

News

Press Releases

Research Reports

GlobeNewswire
Novan to Participate in the Virtual Investor Roundtable Event
– Live moderated video webcast discussion among management and Pediatric Dermatology Thought Leader on Wednesday, November 17th at 1:00 PM ET – DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, joined by a pediatric dermatology thought leader, will participate in the Virtual Investor Roundtable Event on Wednesday, November 17, 2021 at 1:00 PM ET.As part
Zacks Small Cap Research
NOVN: KINSOLUS: A Solution for Molluscum
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Third Quarter 2021 Results On November 10, 2021, Novan Inc. (NASDAQ:NOVN) reported third quarter financial results in a press release concurrent with the filing of Form 10-Q . A conference call and webcast was also held to update investors on financial and operational results. Most recently, the FDA conditionally accepted
GlobeNewswire
Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – – Advancing priority development pipeline assets by progressing SB019, for the treatment of SARS-CoV-2, toward a Phase 1 study in 2022, and SB204, for the treatment of acne vulgaris, toward a registrational Phase 3 study in 2023 – – Company to host update conference call and webcast today at 8:30 a.m. ET